Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect Study of K-877 (Pemafibrate) in Healthy Adults
NCT04742218Phase 1Completed
- Start
- Jan 2021
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pemafibrate in dyslipidemia and hyperlipidemia (2 arms). Primary endpoints: Maximum Plasma Concentration at 24 hours, Area Under the Curve from time 0 to last measurable concentration at 24 hours and 1 more. Started Jan 2021; status: completed.
02
Drugs
pemafibrate
03
Conditions
dyslipidemiahyperlipidemia
Beyond the preview
Go deeper on NCT04742218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04742218.